What insurance plans does Michelle Levy, MD accept?

Aetna, Anthem BCBS Colorado, Apostrophe Health, b SMART, Carrum, Cigna, Colorado Access, First Health, Humana Medicare Advantage, *Kaiser (depending on market), Medicare, Medicaid, Multiplan/PHCS, Optum Health / Optum Care CO, PHPprime, Rocky Mountain Health Plans Medicaid Prime, CHP+, Valley, Monument Tier 2 & CO Doctors Plan, SMS, TRICARE/HealthNET, United Healthcare

Michelle Levy, MD

Medical Oncologist / Hematologist

Accepting new patients

Skip to section

Provider Biography

Dr. Levy is a board-certified medical oncologist and hematologist specializing in malignant and benign hematology. She treats blood cancers including leukemia, multiple myeloma, Non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma.

Dr. Levy also treats patients with benign blood disorders including clotting, bleeding, hereditary and pregnancy-related conditions as well as hemochromatosis, iron deficiency, anemia, thrombocytopenia. In addition, she performs surgical clearances.

She participates in a bi-monthly city-wide hematology tumor board to review complex cases and collaborate on patient care with other blood cancer experts and discuss cancer treatment options. Dr. Levy practices evidence-based medicine and follows National Comprehensive Cancer Network (NCCN) guidelines.

Provider Specialties

Benign and Malignant Hematology
Bleeding Disorders
- Thrombocytopenia
Blood Disorders
- Anemia
- Pregnancy-Related Blood Disorders
Bone Marrow Biopsy
Clotting Disorders
Hereditary Hemochromatosis
Hodgkin's Lymphoma
Iron Deficiency
Leukemia
- Overview
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
Multiple Myeloma
- Amyloidosis
- Monoclonal Gammopathy (MGUS)
- Smoldering Multiple Myeloma
Myeloid Malignancies
Myeloproliferative Neoplasms
- Polycythemia Vera
- Essential Thrombocytosis
- Primary Myelofibrosis
Myelodysplastic Syndromes
Non-Hodgkin's Lymphoma
- Overview
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Peripheral T-Cell Lymphoma and Other T-Cell Lymphomas
Surgical Clearances

Care Philosophy

My goal is to provide my patients with a compassionate whole-person approach to care. I take the time to listen to my patients and understand their needs, concerns, and goals. I focus on educating my patients and their families, such that they can truly understand their diagnosis and feel confident in the plan of care.

Care Team

Beth Manthey
View Profile

Locations

1800 N. Williams St., Ste. 200
Denver, CO 80218

303-388-4876

Request Appointment View Details

10107 Ridgegate Pkwy., Ste. 200
Lone Tree, CO 80124

303-925-0700

Request Appointment View Details

Skip to section

Education

Fellowship

Medical Oncology & Hematology, Penn State Hershey Medical Center, Hershey, PA

Residency

Internal Medicine, Kaiser Permanente Medical Center, Santa Clara, CA

Medical School

Emory University School of Medicine, Atlanta, GA

Board Certifications

Hematology
Internal Medicine
Medical Oncology

Memberships

American Society of Clinical Oncology
American Society of Hematology

Articles

Videos

Publications

Show Publications
- Levy MA, Claxton DF. “Therapeutic inhibition of BCL-2 and related family members.” Expert Opin Investig Drugs. 2017;26(3):293-301.
  
  Michelle Levy; Liisa Lyon; Erika Barbero; John Wong; Jennifer Marie Suga; Danny Sam; Minggui Pan. “Histologic Grade is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.” Med Sci (Basel). 2017 Dec 11;5(4):34.
  
  Abstracts
  
  Pu, J. J., Ehmann, W. C., Liao, J., Capper, C., Levy, M., Claxton, D. F., Rybka, W. B., Hohl, R. J., & Epner, E. M. (2016). “The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma.” Blood, 128(22), 1792.
  
  Levy M.A.; Carrasquillo, Y.; Drobish, J.; Alter, B.J.; Gereau, R.W. “Group I mGluRs activate ERK signaling in GABAergic neurons of the central nucleaus of the amygdala and contribute to mechanical hypersensitivity in mice.” Society for Neuroscience Abstracts.